al. [61] developed interesting radiomics models to predict HER-2 gene status (which relates to a more aggressive subtype of BC), therefore providing a novel tool to support clinical decision-making, and attempting to overcome some limitations of the fluorescence in situ hybridization and immunohistochemistry of HER-2, especially those regarding the representativeness of the bioptic sample when withdrawn by the patient. Here, ERBB2 is linked to breast cancer.